Drug pricing and competition policy: evolution or revolution?

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.340, 2001-01, pp. : 3-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CER − evolution or revolution?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 630, 2011-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Drug pricing: what's to be done?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 318, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Is differential pricing the way of the future for the drug industry?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 644, 2012-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Reflections on the Changing Face of German Pharmaceutical Policy: How Far is Germany from Value-Based Pricing?

By Gerber Andreas

PharmacoEconomics, Vol. 29, Iss. 7, 2011-07 ,pp. : 549-553

Adis International

Access to resources Recommend Favorite

Do reference-based pricing policies really contain drug costs?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 320, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite